Intravitreal injection

Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates

Retrieved on: 
Wednesday, May 4, 2022
COVID-19, U.S. Securities and Exchange Commission, Retinal detachment, Nasdaq, Mouse, GFP, GLOBE, Company, Securities Exchange Act of 1934, Securities Act of 1933, AAV, Retina, ARVO, Research, Eye, Food, CO, Patient, Security (finance), Association for Research in Vision and Ophthalmology, Optic nerve, Intravitreal injection, Partnership, Association, Animal, Data analysis, Inflammation, Annual report, Drug Quality and Security Act, Patent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Administration, Tissue, Tropism, Liver, Terminology, Technology, Annual general meeting, Central nervous system, SLO, Capsid, Therapy, Vaccine, List of Roman birth and childhood deities, Ophthalmology

The data was featured in a poster presentation entitled AAV204, a Novel AAV Capsid, Demonstrates Superior Macular Transduction Following Para-Retinal Administration in Non-Human Primates.

Key Points: 
  • The data was featured in a poster presentation entitled AAV204, a Novel AAV Capsid, Demonstrates Superior Macular Transduction Following Para-Retinal Administration in Non-Human Primates.
  • AAV204, a novel adeno-associated virus (AAV) capsid from Abeonas in-licensed AIM capsid library, has previously been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and non-human primates.
  • Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases.
  • Abeonas novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting  

Retrieved on: 
Tuesday, May 3, 2022
Vance DeGeneres, Euronext, DME, Integrin, Research, ARVO, Patient, Fibrosis, Intravitreal injection, Association, Diabetic retinopathy, Retina, Inflammation, Macular edema, Allograft inflammatory factor 1, Diabetes, Association for Research in Vision and Ophthalmology, RATS, Central retinal vein occlusion, Annual general meeting, STZ, Pharmaceutical industry, Ophthalmology, Carlo Emilio Bonferroni

Preclinical data shows THR-687s potent inhibition of vascular permeability, inflammation and reactive gliosis in diabetic rats supporting evidence of clinical utility of THR-687 in multiple retinal diseases.

Key Points: 
  • Preclinical data shows THR-687s potent inhibition of vascular permeability, inflammation and reactive gliosis in diabetic rats supporting evidence of clinical utility of THR-687 in multiple retinal diseases.
  • Targeting RGD-binding integrins is known to affect multiple disease hallmarks such as vascular leakage, inflammation, angiogenesis and fibrosis.
  • The preclinical study investigated the therapeutic potential of THR-687, a potent pan-RGD integrin antagonist, in the streptozotocin (STZ)-induced diabetes rat model.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.

Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous anti-VEGF wet AMD and DME Candidate at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Retrieved on: 
Monday, May 2, 2022
Neuro, COVID-19, VEGF, Volunteering, Microglia, CNV, HDS, Choroidal neovascularization, Toxicity, DME, GLOBE, Johns Hopkins University, Safety, ARVO, Research, Eye, CO, Patient, Intravitreal injection, Ashvattha, Association, Animal, HDT, Macrophage, Diabetic retinopathy, Inflammation, Human, Therapy, Association for Research in Vision and Ophthalmology, Neurology, RPE, Covalent bond, Disease, Liver, CEO, Technology, AMD, Annual general meeting, Pathology, VEGFR, Cell, Pharmaceutical industry, Vaccine, Ophthalmology, Ophthalmology

REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced the presentation of safety data from a Phase 1 study of its lead candidate D-4517.2, a potent VEGFR/PDGFR tyrosine kinase inhibitor conjugated to a hydroxyl dendrimer, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in Denver, CO, May 2-4, 2022.

Key Points: 
  • The data showed that single subcutaneous doses of D-4517.2 were safe and well tolerated in healthy subjects at dose levels of 0.25 mg/kg, 0.50 mg/kg and 1.0 mg/kg.
  • Current treatments for wet AMD and DME, degenerative retinal diseases, require invasive, intravitreal injections into the eye, which can be a treatment burden on patients and doctors.
  • The Phase 1 study of healthy human volunteers was conducted in three cohorts of 0.25 mg/kg, 0.50 mg/kg and 1.0 mg/kg subcutaneous doses.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022

Retrieved on: 
Tuesday, April 26, 2022
Gene, EMA, Illuminate, Annual report, Lists of diseases, ARVO, ADAR, Annual general meeting, U.S. Securities and Exchange Commission, COVID-19, Association, Ghent University, Philadelphia, Eye, Security (finance), Adenosine deaminase, Research, Life, Retina, Children's Hospital of Philadelphia, RNA, GLOBE, Patient, LCA, Severe cognitive impairment, Western world, Hospital, III, Intellectual property, Leber congenital amaurosis, CEP290, Intravitreal injection, Nasdaq, ProQR, PRIME, Children, Forward-looking statement, Safety, Union, FDA, Mutation, Prevalence, Disease, Risk, RNA transfection, Therapy, Pharmaceutical industry, Vaccine, Ophthalmology

I look forward to continuing to work with ProQR on this investigational treatment.

Key Points: 
  • I look forward to continuing to work with ProQR on this investigational treatment.
  • Leber congenital amaurosis (LCA) is the most common cause of blindness due to genetic disease in children.
  • LCA10 is caused by mutations in the CEP290 gene, of which the c.2991+1655A>G (p.Cys998X) mutation has the highest prevalence.
  • LCA10 leads to early loss of vision causing most people to lose their sight in the first few years of life.

DGAP-News: ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

Retrieved on: 
Tuesday, April 26, 2022
CEO, Daiichi Sankyo, Research, CNS, Brain, Program, IgG4-related ophthalmic disease, Patient, Tissue, Retina, Efficiency, AAV, Intravitreal injection, Heart, Eye, Partnership, Liver, Pharmaceutical industry, Vaccine, Limited

Munich, Germany, April 26, 2022 -- ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Company, Limited ("Daiichi Sankyo") to utilize ViGeneron's novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye diseases. Financial terms are not disclosed.

Key Points: 
  • Munich, Germany, April 26, 2022 -- ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Company, Limited ("Daiichi Sankyo") to utilize ViGeneron's novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye diseases.
  • ViGeneron has worked on this program together with Daiichi Sankyo since early 2021.This follow-on collaboration allows the companies to create and validate vgAAV-based therapeutic candidates for the undisclosed target through in-vivo animal studies.
  • The company is advancing its proprietary gene therapy pipeline to treat ophthalmic diseases, while partnering with leading biopharmaceutical players in retinal diseases, CNS, and other disease areas.
  • ViGeneron's two novel next-generation gene therapy platforms are geared towards addressing the limitations of existing adeno-associated virus (AAV)-based gene therapies.

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

Retrieved on: 
Tuesday, April 26, 2022
CEO, Daiichi Sankyo, Research, CNS, Brain, GLOBE, Program, Patient, IgG4-related ophthalmic disease, Tissue, Retina, Efficiency, AAV, Intravitreal injection, Heart, Eye, Partnership, Disease, Liver, Pharmaceutical industry, Vaccine, Limited

MUNICH, Germany, April 26, 2022 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) to utilize ViGenerons novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye diseases.

Key Points: 
  • MUNICH, Germany, April 26, 2022 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) to utilize ViGenerons novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye diseases.
  • ViGeneron has worked on this program together with Daiichi Sankyo since early 2021.This follow-on collaboration allows the companies to create and validate vgAAV-based therapeutic candidates for the undisclosed target through in-vivo animal studies.
  • The company is advancing its proprietary gene therapy pipeline to treat ophthalmic diseases, while partnering with leading biopharmaceutical players in retinal diseases, CNS, and other disease areas.
  • ViGenerons two novel next-generation gene therapy platforms are geared towards addressing the limitations of existing adeno-associated virus (AAV)-based gene therapies.

Global Diabetic Retinopathy Market is Projected to Reach a CAGR of 6.4%, in Terms of Value, Between 2022 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 19, 2022
Diabetes, Pharmaceutical, Health, Other Health, Awareness, Diabetic retinopathy, COVID-19, Laser surgery, Population Reference Bureau, Ageing, Diagnosis, Incidence, Diabetes, International Diabetes Federation, CAGR, Marriage age in the United States, Patient, Severe cognitive impairment, Population, Intravitreal injection, Management, Visual impairment, Patellar tendon rupture, USD, Medical device, Pharmaceutical industry, Vitrectomy

The global diabetic retinopathy market size is expected to reach USD 13.8 billion by 2030 registering a CAGR of 6.4%.

Key Points: 
  • The global diabetic retinopathy market size is expected to reach USD 13.8 billion by 2030 registering a CAGR of 6.4%.
  • According to the International Diabetes Federation, in 2021 there were about 537 million diabetic cases, which is projected to rise to 643 million by 2030 and 783 million by 2045.
  • Studies suggest that in 2020 the number of diabetic retinopathy cases was about 103.12 million; the cases are expected to reach 160.5 million by 2045.
  • The large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market

DGAP-News: ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

Retrieved on: 
Tuesday, April 12, 2022
Risk, Retina, Heart, IRD, AAV, Liver, CNS, IgG4-related ophthalmic disease, CEO, Intravitreal injection, Tissue, Regeneron Pharmaceuticals, Collateral damage, Brain, Efficiency, Retinal detachment, Patient, Pharmaceutical industry, Vaccine

Munich, Germany, April 6, 2022 -- ViGeneron GmbH, a next-generation gene therapy company, today announced a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals Inc. (Regeneron) to develop and commercialize a gene therapy product based on ViGeneron's novel engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD).

Key Points: 
  • Under the terms of the research collaboration, Regeneron and ViGeneron will create and validate vgAAV-based therapeutic candidates for one undisclosed IRD target.
  • Regeneron has an option for an exclusive license to develop, commercialize and manufacture the vgAAV-based product for the specific target.
  • ViGeneron is eligible to receive an option exercise fee, development and commercial milestone payments, plus royalties on net sales.
  • ViGeneron's two novel next-generation gene therapy platforms are geared towards addressing the limitations of existing adeno-associated virus (AAV)-based gene therapies.

ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

Retrieved on: 
Wednesday, April 6, 2022
Risk, Retina, Heart, IRD, AAV, CNS, Liver, IgG4-related ophthalmic disease, CEO, Intravitreal injection, Tissue, Regeneron Pharmaceuticals, Collateral damage, Brain, GLOBE, Efficiency, Retinal detachment, Patient, Pharmaceutical industry, Vaccine

Under the terms of the research collaboration, Regeneron and ViGeneron will create and validate vgAAV-based therapeutic candidates for one undisclosed IRD target.

Key Points: 
  • Under the terms of the research collaboration, Regeneron and ViGeneron will create and validate vgAAV-based therapeutic candidates for one undisclosed IRD target.
  • Regeneron has an option for an exclusive license to develop, commercialize and manufacture the vgAAV-based product for the specific target.
  • ViGeneron is eligible to receive an option exercise fee, development and commercial milestone payments, plus royalties on net sales.
  • ViGenerons two novel next-generation gene therapy platforms are geared towards addressing the limitations of existing adeno-associated virus (AAV)-based gene therapies.

Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)

Retrieved on: 
Wednesday, March 16, 2022
NDA, Twitter, Quality of life, Time, Severe cognitive impairment, GLOBE, Patient, APLS, U.S. Securities and Exchange Commission, Annual report, ID, Private Securities Litigation Reform Act, Conference call, Geographic atrophy, AMD, FDA, Nasdaq, Endophthalmitis, Central retinal vein occlusion, Science, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Lists of diseases, Injection, Food, Retinal, Creativity, Inflammation, Fast Track, Population, Webcast, C3, New Drug Application, Retinal vasculitis, United, Intravitreal injection, LinkedIn, Silviculture, Pharmaceutical industry, Conference, OAKS

It is exciting to see these positive data with pegcetacoplan, which showed continuous and potentially improving effects over time.

Key Points: 
  • It is exciting to see these positive data with pegcetacoplan, which showed continuous and potentially improving effects over time.
  • The treatment effects observed in DERBY were comparable with OAKS during months 6-18.
  • Data at 18 months from the combined studies show the potential for improving treatment effects with pegcetacoplan over time.
  • Pegcetacoplan is the only therapy to continuously reduce GA lesion growth across a large and broad patient population in Phase 3 studies.